The U.S. Food and Drug Administration is still preparing a major reform of the Generally Recognized as Safe, or GRAS, framework, but the timetable has moved back. The federal regulatory agenda now lists December 2026 as the planned publication date for a proposed rule requiring GRAS notices for certain uses of human and animal food substances.
One distinction is essential: December is the expected date for a proposed rule, not the implementation date of a final mandatory-notification system. The existing framework remains in place while the proposal is developed, reviewed and opened to public comment.
Under current rules, a company that concludes a food substance is GRAS under its intended conditions of use may voluntarily notify the FDA. It may also rely on its own GRAS conclusion without submitting that determination to the agency. The FDA strongly encourages notification, but submission is not currently mandatory.
The system has been criticized because a substance can enter the food supply without the FDA knowing that a company has reached a GRAS conclusion. The legal safety standard is not necessarily lower than for a food additive, but the regulator and the public may have limited visibility into the evidence used.
FDA’s planned reform would require notifications for new substances claimed to be GRAS. The regulatory agenda also states that uses covered by the mandatory requirement could be presumed not to qualify as GRAS when the notification obligation has not been met.
The change would move the system away from largely private safety conclusions and toward mandatory disclosure and regulatory visibility.
For suppliers of food additives and functional ingredients, the commercial consequences could be significant. Developers of sweeteners, preservatives, enzymes, fermentation-derived ingredients, botanical extracts and nutrition compounds may need more complete packages covering identity, manufacturing, toxicology, dietary exposure and intended conditions of use.
Companies would still bear primary responsibility for demonstrating safety, but the supporting information would be more likely to reach the FDA and appear in a public-facing inventory.
Greater transparency will also mean higher compliance costs. The government’s regulatory agenda identifies expenses associated with revising standard operating procedures, preparing submissions and, for manufacturers in non-English-speaking countries, translating documents.
For smaller ingredient developers and foreign suppliers, the difficult part may not be generating one additional study; it may be assembling years of technical information into a submission that meets U.S. regulatory expectations.
The delay gives industry more time to prepare, but it also extends uncertainty. Companies still do not know the precise scope of the proposal, how existing independently concluded GRAS uses will be treated or how long any transition period will last.
Large ingredient groups generally maintain regulatory, toxicology and quality teams that can absorb the additional work. Smaller food-technology companies may need outside consultants or partnerships with larger suppliers. Mandatory notification could therefore widen the compliance gap between established companies and early-stage innovators.
The reform may also affect the speed of product development. Stronger notification requirements could reduce the use of poorly documented ingredients and improve public confidence. On the other hand, insufficient FDA review capacity could slow the introduction of legitimate new substances.
The central issue is therefore not simply that the proposal has been delayed. It is whether the eventual system can increase transparency without turning regulatory filing capacity into the decisive advantage in food-ingredient innovation.
